Tuesday 29th March Plenary sessions are shared across all conferences


Veterinary, Tuesday 29 March 2016

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Gregory A. Poland

Vaccinomics and vaccinology 3.0 – The way forward

  • Vaccinomics, adversomics and the immune response network theory: Individualized vaccinology in the 21st century
  • New understandings of how vaccines stimulate immune responses, new biomarkers for vaccine response, and facilitate the understanding of what genetic and other factors might be responsible for rare side effects due to vaccines
  • Integrating increasingly complex high throughput data into descriptive and predictive equations for immune responses to vaccines
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr. Leonard Friedland

Vaccine adjuvant science: Understanding modern vaccines

  • Novel adjuvant systems under investigation by GSK and safety considerations
  • Learning and challenges in combining adjuvants including pre-clinical and clinical experience
  • Experience and considerations for use in special populations
  • Potential application of adjuvants to future vaccines (experience with adjuvanted investigational zoster vaccine), and adjuvant communication to healthcare providers and patients
Dr. Leonard Friedland, VP, Scientific Affairs and Public Health Vaccines, North America, GSK
Dr Peter Hotez

Developing a new generation of neglected disease vaccines

  • New human hookworm and schistosomiasis vaccines now in clinical trials and earlier stage vaccines for Chagas disease, leishmaniasis
  • Building vaccine development capacity in critical areas threatened by poverty and conflict, including ISIS held territories with the White House and State Department US Science Envoy
Dr Peter Hotez, President of the Sabin Vaccine Institute and Dean of National School of Tropical Medicine, Baylor College of Medicine

Networking Coffee Break



Vaccinating the anti-vaxxers
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences

The need for a vaccine development fund 
Prof Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania & Executive Advisor, Sanofi Pasteur
Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic

How can the pharma/CRO industry better collaborate with the site networks?
Lynlee Burton, Director of Project Delivery – Vaccines, PRA Health Sciences

Practical issues around inclusion/exclusion criteria and protocol design with their impact on time-lines, data collection, and quality of subjects
Prof William B. Smith, Founder, President, and Principal Investigator NOCCR/VRG

Overcoming hurdles in technology transfer & IP
Dr Mukul Ranjan, Senior Advisor for Innovation and Technology Transfer, National Institute of Allergy and Infectious Diseases

Considerations for global clinical vaccine studies
Dr Cynthia Dukes, VP Global Project Management, Vaccines, Infectious Diseases, Women’s Health and Primary Care, ICON Clinical Research

New approaches to accessing patient populations: Adults in G8 markets, middle income countries and helping Gavi-funded governments reach the fifth child
Tara Azimi, Expert Associate Principal, McKinsey & Company
Aliza Apple, Engagement Manager, McKinsey & Company

Designing effective processes to enable scalability of vaccine products
Dr Joseph G. Joyce, Director, Vaccine Process Development, Merck Research Laboratories

A Transition to Targeted or “Smart” Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination
Dr Blaine Pfeifer, Associate Professor, Chemical and Biological Engineering Department, State University of New York at Buffalo

The issue of virally-induced cancers: Barriers to awareness
Dr Lopa Mishra, Director, Center for Translational Research Department of Surgery and GWU Cancer Center, George Washington University

From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is to enhance the blood markers beyond serum antibody?
Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg

Challenges and Opportunities in Conducting Clinical Trials in West Africa

Dr David Hoover, Senior Medicial Advisor, Clinical RM
Dr Kevin J. Gilligan, Senior Scientific Advisor, Clinical RM

Zika virus: Challenges for medical countermeasure development
Dr Robert Malone, CEO and Consultant, RW Malone MD, LLC
Pre-clinical biomarkers of safety and efficacy in vaccine design and development
Dr Michael Vajdy, Co-Founder, President and Chief Scientific Officer, Epito Genesis Inc
Adjuvants and technology advancements driving vaccine R&D
Dr Michel De Wilde, Former Senior Vice President R&D of Sanofi Pasteur & Owner, MDW Consultant LLC


Networking Lunch

Dr Heather Sings

An interactive point-count point discussion: Polysaccharide vs conjugate pneumococcal vaccine

  • Policy recommendations for pneumococcal vaccination around the world
  • Amount of disease caused by vaccine serotypes
  • Indirect protection in adults from pediatric use of PCV13
  • Vaccine effectiveness and other immunologic considerations
  • Carriage, duration of protection and cost effectiveness
Dr Heather Sings, Senior Director and Medical Lead, Pneumococcal Vaccines, Pfizer
Dr Melvin Kohn, Medical Director for Adult Vaccines, Merck Vaccines
Dr Laura York

An interactive joint presentation on the FDA approved meningococcal B vaccines

  • The science behind different approaches
  • Discussing the different approaches in getting FDA approval
  • Predictions of effectiveness in additional strains
Dr Laura York, VP, Global Meningococcal Vaccines, Medical Development and Scientific/Clinical Affairs, Pfizer
Dr Rino Rappuoli, Chief Scientist, GSK Vaccines
Dr Wellington Sun

Regulating vaccines at the FDA: Development and licensure of Ebola vaccines

  • What have we learnt from the Ebola crisis?
  • How quickly can we work together to help speed up the process of licensure?
  • How will we respond to the next threat?
Dr Wellington Sun, Director Division of Vaccines and Related Products Applications CBER, U.S. Food and Drug Administration

Networking coffee break

James Mansi

A century of vaccine development & innovation: Ensuring novel influenza vaccines are available to meet the needs of diverse patients groups

  • Vaccines developed for the young, the old, and everyone in between
  • Moving from traditional needle and syringe to innovative needle-free delivery systems
  • Transition from traditional trivalent flu vaccines to quadrivalent, cell culture based, and adjuvanted vaccines
James Mansi, Global Head, Medical Affairs, Novartis Influenza Vaccines
Dr Gary Nabel

What is the vision for a HIV vaccine? Has it changed in the last decade?

  • Update on the clinical trials and their progress
  • Has the sense of urgency for a HIV vaccine lost its momentum with effective preventative methods that can stop/limit transmission
  • Could HIV eliminate itself eventually?
  • The vision for a vaccine to replace all preventative methods 
Dr Gary Nabel, Senior Vice President and Chief Scientific Officer, Sanofi Inc
Rahul Singhvi

The future sustainability of vaccines - What pressure does the industry suffer from that could prevent access to vaccine?

-How will the industry look in 10 years? Understanding the industry dynamics and factors that will give you a competive advantage
-Addressing the obstacles poised in market access and manufacturing
-How to treat the vaccine industry differently to the pharmaceutical industry as a whole, using value based pricing as an example
Rahul Singhvi, Chief Operating Officer, Takeda Vaccines, Inc.
Dr Gregory A. Poland

Chair’s closing remarks and close of congress day 1

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation

Pre-Awards Networking Drinks Reception


Gala Dinner & ViE Awards Ceremony

last published: 24/Mar/16 11:26



Veterinary, Wednesday 30 March 2016

Dr Cyril Gay

Chair’s opening remarks

Dr Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Dr Cyril Gay

Progression in veterinary vaccine R&D: New technologies and research breakthrough

  • Research into novel vaccine technologies
  • Developing commercial veterinary vaccines against viral, bacterial and parasitic diseases within a variety of animal species
Dr Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Dr Mahesh Kumar

Influenza - A continuing threat in multiple species

  • Recent developments in the avian and canines species and the industries response to address the need 
Dr Mahesh Kumar, Vice President, Global Biologics Research, Zoetis
Mr Marcelo Paniago

Developing an achievable agenda to eradicate avian influenza

  • What are the most promising approaches to the eradication of avian Influenza?
  • Considering how the industry reacts to the threat
  • Where future vaccine development should focus
Mr Marcelo Paniago, Director Global Veterinary Services Poultry, Ceva Santé Animale

Networking coffee break

Dr Daniel Peréz

The need for an interspecies universal flu vaccine to protect both human and animal health

  • Preventing the capacity in which influenza strains can evolve and adapt, crossing the species barrier and spreading to other individuals within the new species
  • A one health approach to reduce the frequency of inter-species transmission events that occur
  • Consequences of inter-species transmission not only for human health, but also for the health of wild animals and the success of industries such as poultry farming
Dr Daniel Peréz, Chair in Poultry Medicine, University of Georgia - College of Veterinary Medecine
Dr. Konrad Stadler

The journey in developing a vaccine against bovine viral diarrhoea

  • The presence of antibiotic resistance genes is one of the drawbacks of modern gene therapy and DNA vaccine applications
  • By using plasmid DNA (pDNA) for vaccination, a novel system can be developed without any antibiotic resistance risk
The considerable potential for human and animal health care vaccines
Dr. Konrad Stadler, Head of R&D Vaccines EU, Boehringer Ingelheim GmbH

Rift Valley Fever Countermeasures- from agent identification to vaccine supply

  • Review of current status of animal countermeasures for preventing and controlling Rift Valley Fever
  • Overview of the feed the future program from USAID
  • New technologies and delivery methods being developed for dissemination in affected areas

Networking Lunch

Dr Andrew Potter

Reverse vaccinology approaches to disease in Cattle

  • Why is reverse vaccinology appropriate to these diseases?
  • Vaccines for Contagious Bovine Pleuropneumonia and Histophilus somni infection
  • The impact our developments may have on future developments of efficacious vaccines
Dr Andrew Potter, Director and Chief Executive Officer, VIDO-InterVac
Prof Annie De Groot

Using immunoinformatic tools to construct and test an epitope-driven IAV vaccine against swine influenza

  • Identifying T cell epitopes conserved in seven representative strains of IAV
  • Immunizing with epitope plasmid DNA vaccines encoding strings of class I and II epitopes
  • Demonstrating capacity to predict immunogenic T cell epitopes and demonstrating its potential for use in the design of vaccines for swine
Prof Annie De Groot, Chief Executive Officer, Chief Scientific Officer and Director, EpiVax Inc
Mr Mark Wood

Emerging regulatory issues impacting the global development, registration, and use of veterinary vaccines?

  • Current hurdles for conventional vs. products of biotechnology
  • Sterility and extraneous agent testing and requirements for seed and Ingredients of animal origin
  • Ripple effects of changing regulations on global product: registrations, sale, distribution, and use
Mr Mark Wood, Director, Regulatory Affairs-Biological New Projects, Merial

Networking coffee break

Tim Leard

Recombinant Vaccine Technology in Veterinary Medicine

  • Overview of licensed recombinant biologicals in veterinary medicine
  • Indications and applications for these technologies in animal health
  • Perspectives on their use and future opportunities
Tim Leard, Director of Biologics Research and Development, Merial
Dr Hank Harris

Update on how a rapid response RNA Particle technology is addressing veterinary disease outbreaks

  • The first Avian Influenza vaccine licensed in the US for Highly Pathogenic H5N2
  • Developing the Porcine Epidemic Diarrhea Virus (PEDv) vaccine and the platform’s applications to other vaccine areas
Dr Hank Harris, President, Harrisvaccines & Merck Animal Health

New prophylactic solutions in animal health and opportunities in human vaccine arena

  • Novel anti-infectious vaccines against parasitic diseases
  • New generation of live and attenuated vaccines
  • Genetically engineered for safetyor safety
Dr Keith Haffer

Methods for improving immunological responses: Anti-somatostatin Vaccine example

  • Methods for increasing an immunological response to a target hormone antigen by means of defined linker polypeptides and carrier protein.
  •  Non-traditional immune responses with anti-somatostatin vaccines.
  • Potential for new vaccines utilizing linear B-cell epitopes.
Dr Keith Haffer, Chief Scientific Officer, Braasch Biotech Llc
Dr Nikolai Petrovsky

One health: Adjuvants suitable for animal and human vaccine use

  • Measuring efficacy, toxicity and correlates of protection in various species
  • Common technologies to accelerate vaccine protection in animals and humans 
  • Novel adjuvant combinations for veterinary and human vaccines
  • Enhancing protection of neonatal animals and humans
  • Developing shared vaccines for animals and humans; influenza, JEV, West Nile, anthrax
Dr Nikolai Petrovsky, Chairman, Vaxine Pty.
Dr Cyril Gay

Chair’s closing remarks and close of congress day 2

Dr Cyril Gay, Senior National Program Leader, A.R.S. National Programs
last published: 24/Mar/16 11:26



Veterinary, Thursday 31 March 2016

Dr Cyril Gay

Chair’s opening remarks

Dr Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Dr Francois Maree

Structural design of improved vaccines for the effective control of foot-and-mouth disease in endemic regions

  • FMD vaccine antigens are inherently unstable in mild acidic pH & elevated temperatures and believed to be less immunogenic due to degradation before & after inoculation
  • Therefore, to be effective, FMD vaccines need to be structurally improved
  • New understandings of protein-protein interactions in the virus capsid or inactivated particles might help in the design of improved vaccine seed viruses
Dr Francois Maree, A.R.C. O.V.I. Transboundary Animal Diseases Programmed
Dr Joanne Maki

Controlling rabies: Eradicating rabies means combatting it at its animal source

  • It remains endemic in a number of countries, causing a significant public health impact
  • Mass vaccination of dogs is the best way to interrupt the disease’s infectious cycle between animals and humans
  • Reducing the risk of infection in vulnerable populations (wildlife, stray and domestic animals) creates a barrier between the animal source and humans
Dr Joanne Maki, Veterinary Public Health, Merial
Dr Jennifer Filbey

Innovations in expression technologies to enable oral delivery for animal health vaccines: Opportunities and challenges

  • Orally delivered vaccine candidates have demonstrated proof-of-concept for successful immunological outcomes using plant-based expression platforms
  • Commercially viable systems are now possible with recent improvements in the accumulation and processing of the antigen
  • The current improved system has demonstrated efficacy, low cost, stability at ambient temperatures and ease of administration
Dr Jennifer Filbey, President, Mazen Animal Health

Networking coffee break

Dr Ming-Chung Kan

Vaccine delivery system X (VADEX): A vaccine platform that stimulates prolonged humoral immune response

  • Dissecting the mechanism of vadex
  • Application of vadex in veterinary vaccine
  • Animal vaccines in development using vadex platform
Dr Ming-Chung Kan, Founder, vaxsia
Dr. Patricia Lawman

Development of a cell/gene therapy for the treatment of veterinary cancers

  • Combining cell and gene therapy to initiate tumor-specific humoral and cellular immune responses
  • Applications in canine, feline and equine malignancies
  • Cell/gene combination allows for the “personalization” of immune-oncology therapy even in an off-the-shelf formulation 
Dr. Patricia Lawman, Chief Executive Officer, Morphogenesis I.N.C.

Networking Lunch

Dr Gregory A. Poland

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
Dr Thomas Breuer

ABCs of Supply and Demand: Creating the Future

-    Appreciating the intricacies of the vaccine industry: Roles and structure of the Industry, R&D and manufacturing cycles    
-    Industry future: Health solutions and business challenges
-    How we achieve business sustainability and meet global vaccine needs
-    Measuring and recognizing the full economic and social value of vaccines
-    What the industry, partners and governments need to do
Dr Thomas Breuer, Senior Vice President, Chief Medical Officer, G.S.K. Vaccines
Dr Carol J. Baker

Do we need a new strategy for maternal immunization?

  • Are vaccines that benefit the baby more than the mother acceptable?
  • Have we progressed in our understanding of maternal and neonatal vaccine immunology?
  • Where are we with development of vaccines that affect maternal and infant health (e.g., group B Streptococcus, respiratory syncytial virus, pertussis and influenza)?
Dr Carol J. Baker, Head of Infectious Disease Professor of Pediatrics, Baylor College of Medicine
Dr Jerome Kim

A MERS vaccine: Doing research and vaccine development preemptively

  • For-profit vaccine companies will find it difficult to make vaccines that are not used except in an emergency
  • Governments can and do fund the production of vaccines that are not commercially viable but bear the risks of discovery and the burden of development
  • MERS is not the herald of an impending epidemic apocalypse but public health, and the vaccines necessary to maintain it, is not free or easy
Dr Jerome Kim, Director-General, International Vaccine Institute
Dr Gregory A. Poland

Chair’s closing remarks and close of congress

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and Foundation
last published: 24/Mar/16 11:26